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“Any fool can know. The point is to understand”  
Albert Einstein 
 
Coronavirus disease (COVID-19) has sneakily entered our lives early on in 2020 and the 
adverse health effects associated with it continue. We now understand more about the virus 
and about how to manage patients. Large-scale studies have been initiated across the globe 
and one provided an ally in our fight against COVID-19 in an old fashioned drug, 
dexamethasone reducing mortality 1. Others showed reduction in hospital stay 2 or simply 
reinforced the safety of continuing medications during COVID-19 3. We have also realised 
how catastrophic the virus can be. We learned that severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which causes COVID-19, enters the cells using Angiotensin-
converting enzyme 2 (ACE2) receptors. These receptors are found abundantly not only in 
the pulmonary but also other organ systems such as the cardiovascular and gastrointestinal 
systems. Consequently, extra-pulmonary effects of COVID-19 are not at all surprising. With 
an increasing number of cases and a forthcoming second wave infection, clinicians must be 
aware of these multisystem manifestations. In this article, we aim to discuss the short and 
long-term impact of COVID-19 on the respiratory and some of the other major organ 
systems in the human body.  
 
Respiratory system 
 
The principal manifestation of COVID-19 is in the lungs, where respiratory failure is a leading 
cause of death. SARS-CoV-2 enters human cells by binding to the angiotensin-converting 
enzyme 2 (ACE2) receptors, that are highly expressed in the alveolar type 2 cells (AT2), 
explaining the vulnerability of the respiratory system 4. 
 
Post-mortem studies elucidate the observed pathology upon macroscopic and microscopic 
examinations 5. Gross lung findings include patchy to diffuse consolidation, severe interstitial 
congestion, and thromboembolism while histology demonstrates hyaline membranes, 
extensive capillary congestion, and microthrombi in alveolar capillaries, consistent with 
exudative diffuse alveolar damage (DAD) (Figure 1). Whilst aforementioned findings resemble 
those found in acute respiratory distress syndrome (ARDS), COVID-19-associated ARDS 
displays a peculiar phenotype owing to dissociation between severity of hypoxaemia and 
relative maintenance of lung mechanics 6.                   
 
Despite COVID-19-associated ARDS meeting the criteria, it has been proposed that patients 
developing it could be categorised into type 1 ‘non-ARDS’ and type 2 ‘ARDS’ depending on 
lung compliance 6. Distinction between them can be made based on CT scans (Figure 2) or, 
albeit substandard, response to positive end-expiratory pressure (PEEP). Type 1 patients 
exhibit severe hypoxaemia with reasonable lung compliance while type 2 patients exhibit 
severe hypoxaemia with poor lung compliance. This has important clinical implications when 
deciding management in the intensive care unit (ICU).    
 
 
Cardiovascular system 
 
Systemic inflammation in response to the SARS-CoV2 infection, in addition to ongoing 
hypoxia secondary to severe pneumonia or ARDS, causes increased cardiometabolic 
demand and myocardial oxygen supply/demand mismatch 7 leading to myocardial damage 8. 
Myocardial injury, in turn, has been shown to be independently associated with high 
mortality and various complications such as ARDS and electrolyte disturbances 9, increasing 
the risk of arrhythmias. There is also rising awareness of acute plaque rupture and 
consequently, acute coronary events in patients with underlying coronary artery disease 7.  
 
Additionally, the surge in pro-inflammatory cytokines as part of the systemic inflammatory 
response to COVID-19, can result in myocarditis and other changes including myocardial 
fibrosis (Figure 3), oedema and pericarditis 8,10. Interestingly, all these changes were seen in 
much younger non-hospitalised patients and were associated with adverse events and poor 
prognosis 8.  
 
Moreover, new evidence demonstrates COVID-19 induced cardiac changes might not be 
limited to the short term (Figure 4) 8. A study by Puntmann et al. 10 involving 100 COVID-19 
recovered patients showed lower left ventricular ejection fraction compared to healthy and 
risk factor-matched controls and significantly raised troponin T levels. After a follow up of 71 
days, 78% of patients had abnormal CMR findings. This patients might be in the very early 
stage of cardiac involvement and perhaps need longer follow-up 8 to identify any potential 
long-term complications, especially in those patients with persistent symptoms attributed to 
COVID-19.  
 
Gastrointestinal including hepatic system 
 
Gastrointestinal (GI) manifestations of COVID-19, have been well-documented 11,12 but the 
underlying mechanisms remain to be further elucidated. ACE2 receptors, found in 
enterocytes and oesophageal epithelial cells, play an important role in regulating intestinal 
inflammation 12 which may, at least in part, explain typical GI symptoms such as diarrhoea, 
nausea and vomiting, which can occur with or without respiratory symptoms 12. 
Unsurprisingly, there has been evidence of the virus in faecal samples even after clearance 
of the virus in the respiratory tract 12, posing questions and challenges for the future. 
 
In addition, a radiology study 13 of 412 patients found bowel wall abnormalities in 31% of CT 
scans and pneumatosis (Figure 5) or portal venous gas in 20% of CT scans in ICU patients. 
Furthermore, 54% of abdominal ultrasounds, performed mainly for abnormal LFTs, were 
suggestive of cholestasis 13, a precursor to liver injury. SARS-CoV2-mediated liver injury can 
be direct through binding of the virus to ACE2 receptors found in cholangiocytes and 
hepatocytes, or indirect through release of cytokines as a part of the immune response 11. 
This aggravates liver cell damage and bile duct cell dysfunction 11. In addition, the liver as 
the principal site of drug metabolism of antiviral drugs such as lopinavir/ritonavir that are 
widely used for COVID-19 may endure further iatrogenic damage during treatment 11.  
 
Dermatological  
 
Skin manifestations were first reported in an Italian cohort where approximately 20% of 
hospitalised patients with COVID-19 and no exposure to new medications showed signs of 
cutaneous involvement 14 . Rashes appeared either before (9%) or after (11%) 
hospitalisation and were described as erythematous, widespread urticarial, or resembling 
chickenpox. Since then skin manifestations have been classified, most comprehensively, in 
a cross-sectional study of 375 patients with COVID-19 and cutaneous lesions 15. The five 
groups identified were: 1) pseudo-chilblain lesions, i.e. acral areas of erythema–oedema 
with some vesicles or pustules (19%, Figure 6a,b), 2) other vesicular eruptions (9%, Figure 
6c), 3) urticarial lesions (19%, Figure 6d), 4) other maculopapules (47%, Figure 7a,b,c), and 
5) livedo or necrosis (6%, Figure 7d) 15. Eruptions occurred before (6%), at the same time 
(57%), or after (37%) the onset of other symptoms and the type of lesion was associated 
with age and disease severity, both increasing from group 1 to group 5. In this study, 
patients received a variety of drug treatments and not all skin manifestations may therefore 
be directly caused by SARS-CoV-2. For example, hydroxychloroquine, may cause skin 
reactions including the rare Stevens-Johnson Syndrome presenting with a pruritic 
erythematous maculopapular eruption that rapidly spreads from distal extremities (Figure 8) 
to the whole body with orolabial and genital mucosal involvement 16. An awareness of 
clinicians to possible skin involvement may help in the diagnosis and management of 
patients with COVID-19. 
 
Neurological 
 
Neurological manifestations of COVID-19 include anosmia and ageusia, which are extremely 
common and are now recognised as key symptoms. A systematic review 17 of 41 studies 
found the neurological manifestations of COVID-19 could be divided into three main 
categories: 1) neurological diseases comorbid with COVID-19, i.e symptoms prior to the 
infection and neurological diseases that also act as a risk factor for developing the virus, 2) 
non-specific neurological manifestations caused by systemic responses and partly the 
neuro-invasive behaviour of the virus, 3) specific neurological symptoms and diseases 
including encephalitis, myelitis and seizures.  
 
One national registry of 125 COVID-19 patients investigating neurological or psychiatric 
disease over a three-week period found 31% to have altered mental status including 16 
(13%) with encephalopathy (Figure 9A-D) 18 and 23 (18%) with a neuropsychiatric diagnosis. 
Of the 23 patients, ten had psychosis; six neuro-cognitive dementia-like syndrome and four 
demonstrated an affective disorder 18. Cerebrovascular events were prevalent at 62% 
(77/125); 46% with ischaemic strokes (Figure 9 E,F) and 7% with intracerebral 
haemorrhages 18. Many patients had known risk factors and were over 60 years old. 
Predominately we are seeing large vessel disease and markers of a prothrombotic state 
suggesting a causal relationship18. However, the extremely high number of cases of SARS-
CoV-2 and the large percentage of those with stroke having other risk factors makes proving 
causality a challenge. Small asymptomatic infarcts have been identified on MRIs and blood 
D-dimer concentrations were raised in many COVID-19 patients 18. The best current 
explanation for the cerebrovascular events is the hyper-coagulable state SARS-CoV-2 
triggers owing to the activation of inflammatory and thrombotic pathways and consequently 
destabilisation of carotid plaque. 
 
Conclusion 
 
This article provides a succinct description of how COVID-19 affects a wide range of organs. 
SARS-CoV2 exerts direct damage of target tissues through binding at the ACE2 receptor 
and indirect effects mediated by systemic inflammation and a prothrombotic state. Although 
the short-term consequences of COVID-19 are becoming clearer over time, the long-term 
effects of this novel virus are not transparent, yet. Highlighting the pulmonary and extra-
pulmonary manifestations of COVID-19 in an open access platform like the one provided by 
Oxford Medical Case Reports will help clinicians to better understand and manage the multi-
organ manifestations of this disease during an imminent second wave of infection.  
 
 
  
References 
 
1.  Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl 
J Med Massachusetts Medical Society; 2020;  
2.  Rochwerg B, Agarwal A, Zeng L, Leo YS, Appiah JA, Agoritsas T, Bartoszko J, 
Brignardello-Petersen R, Ergan B, Ge L, Geduld H, Gershengorn HB, Manai H, 
Huang M, Lamontagne F, Kanda S, Kawano-Dourado L, Kurian L, Kwizera A, Murthy 
S, Qadir N, Siemieniuk R, Silvestre MA, Vandvik PO, Ye Z, Zeraatkar D, Guyatt G. 
Remdesivir for severe covid-19: a clinical practice guideline. BMJ NLM (Medline); 
2020;370:m2924.  
3.  Baral R, White M, Vassiliou VS. Effect of Renin-Angiotensin-Aldosterone System 
Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 
28,872 Patients. Curr Atheroscler Rep Springer Science and Business Media LLC; 
2020;22.  
4.  Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the 
receptor ACE2 expression reveals the potential risk of different human organs 
vulnerable to 2019-nCoV infection. Front Med Higher Education Press; 2020;14:185–
192.  
5.  Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, 
Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, 
Tzankov A. Postmortem examination of COVID‐19 patients reveals diffuse alveolar 
damage with severe capillary congestion and variegated findings in lungs and other 
organs suggesting vascular dysfunction. Histopathology Blackwell Publishing Ltd; 
2020;77:198–209.  
6.  Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit. Care. 
BioMed Central Ltd.; 2020. p. 154.  
7.  Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the 
cardiovascular system: acute and long-term implications. Eur Heart J NLM (Medline); 
2020;41:1798–1800.  
8.  Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L. 
Cardiac involvement in recovered COVID-19 patients identified by magnetic 
resonance imaging. JACC Cardiovasc Imaging Elsevier BV; 2020;  
9.  Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang 
H, Yang B, Huang C. Association of Cardiac Injury with Mortality in Hospitalized 
Patients with COVID-19 in Wuhan, China. JAMA Cardiol American Medical 
Association; 2020;5:802–810.  
10.  Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina 
A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of 
Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From 
Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;  
11.  Zhan K, Liao S, Li J, Bai Y, Lv L, Yu K, Qiu L, Li C, Yuan G, Zhang A, Mei Z. Risk 
factors in patients with COVID-19 developing severe liver injury during hospitalisation. 
Gut BMJ; 2020;gutjnl-2020-321913.  
12.  Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: More than meets the eye. 
Gut. BMJ Publishing Group; 2020. p. 973–974.  
13.  Bhayana R, Som A, Li MD, Carey DE, Anderson MA, Blake MA, Catalano O, Gee 
MS, Hahn PF, Harisinghani M, Kilcoyne A, Lee SI, Mojtahed A, Pandharipande P V, 
Pierce TT, Rosman DA, Saini S, Samir AE, Simeone JF, Gervais DA, Velmahos G, 
Misdraji J, Kambadakone A. Abdominal Imaging Findings in COVID-19: Preliminary 
Observations. Radiology NLM (Medline); 2020;201908.  
14.  Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. 
Dermatology Venereol. Blackwell Publishing Ltd; 2020. p. e212–e213.  
15.  Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, 
Fernández-Nieto D, Rodríguez-Villa Lario A, Navarro Fernández I, Ruiz-Villaverde R, 
Falkenhain-López D, Llamas Velasco M, García-Gavín J, Baniandrés O, González-
Cruz C, Morillas-Lahuerta V, Cubiró X, Figueras Nart I, Selda-Enriquez G, Romaní J, 
Fustà-Novell X, Melian-Olivera A, Roncero Riesco M, Burgos-Blasco P, Sola Ortigosa 
J, Feito Rodriguez M, García-Doval I. Classification of the cutaneous manifestations 
of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 
cases. Br J Dermatol Blackwell Publishing Ltd; 2020;183:71–77.  
16.  Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A. 
Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: A rare case 
report. Oxford Med Case Reports Oxford University Press; 2020;2020:193–195.  
17.  Wang L, Shen Y, Li M, Chuang H, Ye Y, Zhao H, Wang H. Clinical manifestations and 
evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a 
systematic review and meta-analysis. J. Neurol. 2020.  
18.  Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, 
Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020.  
19.  Delcuve GP, Lakowski TM, Su R-C, Beacon TH, Davie JR. SARS-CoV-2 multifaceted 
interaction with human host. Part I: What we have learnt and done so far, and the still 
unknown realities. IUBMB Life IUBMB Life; 2020;  
20.  Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic 
features of COVID-19: A concise review. Pathol. Res. Pract. Elsevier GmbH; 2020. p. 
153097.  
 
 
 
 
 
 
Figures 
 
 
 
 
Figure 1: Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage 
with severe capillary congestion and variegated findings in lungs and other organs 
suggesting vascular dysfunction. Microscopic lung findings. A, Exudative diffuse alveolar 
damage (DAD) showing discrete hyaline membranes and prominent capillary congestion. B, 
Syncytial cells of pneumocyte II origin. C, Extensive capillary congestion without DAD. D, 
Microthrombi in alveolar capillaries. Image reproduced from Menter et al 5 under the terms of the creative 
commons attribution license. 
 
 
 
 
Figure 2: In these 2 patients were recorded the following variables: type 1 lung weight 
(1192 g), gas volume (2774 ml), percentage of non-aerated tissue (8.4%), venous admixture 
(56%), P/F (68), and respiratory system compliance (80 ml/cmH2O); type 2 lung weight 
(1441 g), gas volume (1640 ml), percentage of non-aerated tissue (39%), venous admixture 
(49%), P/F (61), and respiratory system compliance (43 ml/cmH2O). Image reproduced from Gattinoni 
et al 6 under the terms of the creative commons attribution 4.0 international license.                 
 
 
 
 
 
 
Figure 3: Focal Myocardial Fibrosis in Patients Recovered From COVID-19: A 29-year-old 
male patient (first row) underwent cardiac CMR 1 month after the onset of palpitations. A 60-
year-old male patient (second row) underwent cardiac CMR 2 months after the onset of 
palpitations. PSIR sequences in short-axis view (A, C) showed focal LGE (black arrows) in 
inferior and septal segments of left ventricle, respectively. Results were confirmed on the 
PSIR sequences in 2-chamber view (C) and 4-chamber view (D). Images A and 
D demonstrated a small pericardial effusion (white arrow) in both patients. COVID-
19 = Coronavirus Disease 2019; LGE = late gadolinium enhancement; CMR = cardiac 
magnetic resonance; PSIR = phase-sensitive inversion recovery. Image reproduced from Huang et al 8 
under the terms of the creative commons attribution 4.0 international license.           
 
 
 
Figure 4: A and B, Histologic findings in an adult man with severe cardiac magnetic 
resonance (CMR) imaging abnormalities 67 days after COVID-19 diagnosis. High-sensitivity 
troponin T level on the day of cardiac magnetic resonance imaging was 16.7 pg/mL. The 
patient recovered at home from COVID-19 illness with minimal symptoms, which included 
loss of smell and taste and only mildly increased temperature lasting 2 days. There were no 
known previous conditions or regular medication use. Histology revealed intracellular 
oedema as enlarged cardiomyocytes with no evidence of interstitial or replacement fibrosis. 
Panels A and B show immunohistochemical staining, which revealed acute lymphocytic 
infiltration (lymphocyte function–associated antigen 1 and activated lymphocyte T antigen 
CD45R0) as well as activated intercellular adhesion molecule 1. C to F, Representative 
cardiac magnetic resonance images of an adult woman with COVID-19–related 
perimyocarditis. Panels C and D show significantly raised native T1 and native T2 in 
myocardial mapping acquisitions. Panels E and F show pericardial effusion and 
enhancement (yellow arrowheads) and epicardial and intramyocardial enhancement (white 
arrowheads) in late gadolinium enhancement (LGE) acquisition. Image reproduced from Puntmann et 
al 10 under the terms of the CC-BY License. 
 
 
 
 
Figure 5: Coronal CT of the abdomen and pelvis with IV contrast in a 47-year-old man with 
abdominal tenderness demonstrates typical findings of mesenteric ischemia and infarction, 
including pneumatosis intestinalis (arrow) and non-enhancing bowel (*). Frank discontinuity 
of a thickened loop of small bowel in the pelvis (thin arrow) is in keeping with perforation. 
Permissions granted to reproduce image from Bhayana et al 13. 
 
 
Figure 6:  All of the patients shown had confirmed COVID-19. (a, b) Acral areas of 
erythema–oedema with vesicles or pustules (pseudo-chilblain). (c) Monomorphic (i.e. at 
same stages) disseminated vesicles. (d) Urticarial lesions. Permissions granted to reproduce image from 
Casas 15. 
 
 
Figure 7: All of the patients shown had confirmed COVID-19. (a) Maculopapular eruption. 
Some of the lesions are perifollicular. (b) Acral infiltrated papules (pseudovesicular). (c) 
Acral papules (erythema multiforme like). (d) Livedoid areas. Permissions granted to reproduce image 
from Casas 15. 
 
 
Figure 8: Pruritic erythematous maculopapular rash on the distal extremities due to HCQ 
consumption. Image reproduced from Davoodi et al 16 under the terms of the creative commons CC-BY-NC license. 
 
 
 
 
 
 
 
Figure 9: Brain imaging in patients with neurological disease associated with COVID-19 
(A) Hyperintensity along the wall of inferior horn of right lateral ventricle on diffusion-
weighted imaging, indicating ventriculitis. (B) hyperintense signal changes in the right mesial 
temporal lobe and hippocampus with slight hippocampal atrophy, consistent with 
encephalitis (C) Hyperintensity within the bilateral medial temporal lobes and thalami. (D) 
Evidence of haemorrhage, indicated by hypointense signal on susceptibility-weighted 
images, consistent with acute necrotising encephalopathy (E) CT showing ischaemic lesions 
involving the left occipital lobe. (F) Right frontal precentral gyrus of the brain in a man aged 
64 years who deteriorated neurologically after admission to hospital with COVID-19 and was 
diagnosed with acute stroke. Permissions granted to reproduce image from Ellul et al 18. 
 
 
